Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Anti-Infective Agents* ; Antimicrobial Stewardship* ; Methicillin-Resistant Staphylococcus aureus*; Anti-Bacterial Agents/therapeutic use ; Ceftriaxone ; Colombia ; Delivery of Health Care ; Drug Resistance, Bacterial ; Humans ; Meropenem/therapeutic use
    • Abstract:
      Background: Antimicrobial stewardship programs (ASPs) have become a fundamental pillar in optimizing antimicrobial usage, improving patient care, and reducing antimicrobial resistance (AMR). Herein we evaluated the impact of an ASP on antimicrobial consumption and AMR in Colombia.
      Methods: We designed a retrospective observational study and measured trends in antibiotic consumption and AMR before and after the implementation of an ASP using interrupted time series analysis over a 4-year period (24 months before and 24 months after ASP implementation).
      Results: ASPs were implemented according to the available resources in each of the institutions. Before ASP implementation, there was a trend toward an increase in the antibiotic consumption of all measured antimicrobials selected. Afterward, an overall decrease in antibiotic consumption was observed. The use of ertapenem and meropenem decreased in hospital wards, while a decrease in the use of ceftriaxone, cefepime, piperacillin/tazobactam, meropenem, and vancomycin was observed in intensive care units. After ASP implementation, the trend toward an increase of oxacillin-resistant Staphylococcus aureus, ceftriaxone-resistant Escherichia coli, and meropenem-resistant Pseudomonas aeruginosa was reversed.
      Conclusions: In our study, we showed that ASPs are a key strategy in tackling the emerging threat of AMR and have a positive impact on antibiotic consumption and resistance.
      (© 2022. The Author(s).)
    • References:
      Curr Infect Dis Rep. 2018 Jun 29;20(9):31. (PMID: 29959545)
      Antimicrob Agents Chemother. 2006 Jan;50(1):43-8. (PMID: 16377665)
      Rev Chilena Infectol. 2017 Jun;34(3):205-211. (PMID: 28991315)
      Infect Dis Clin North Am. 2016 Jun;30(2):539-551. (PMID: 27208772)
      Glob Health Epidemiol Genom. 2017 May 10;2:e4. (PMID: 29276617)
      Rev Med Chil. 2018 Sep;146(9):968-977. (PMID: 30725016)
      J Hosp Infect. 2004 Jul;57(3):209-16. (PMID: 15236849)
      J Clin Microbiol. 2013 Dec;51(12):3916-20. (PMID: 23926165)
      J Am Dent Assoc. 1953 Feb;46(2):129-34. (PMID: 13022248)
      Med Mal Infect. 2011 Nov;41(11):608-12. (PMID: 21908118)
      Expert Opin Pharmacother. 2015 Feb;16(2):159-77. (PMID: 25496207)
      Infect Control Hosp Epidemiol. 2017 Jun;38(6):756-758. (PMID: 28366177)
      Rev Chilena Infectol. 2019 Feb;36(1):9-15. (PMID: 31095199)
      Clin Microbiol Infect. 2017 Nov;23(11):812-818. (PMID: 28712667)
      J Antimicrob Chemother. 2018 Jun 1;73(6):1464-1478. (PMID: 29554263)
      Int J Antimicrob Agents. 2018 Jun;51(6):829-835. (PMID: 29339297)
      Lancet Infect Dis. 2017 Feb;17(2):e56-e63. (PMID: 27866945)
      Lancet Infect Dis. 2013 Dec;13(12):1057-98. (PMID: 24252483)
      Int J Epidemiol. 2017 Feb 1;46(1):348-355. (PMID: 27283160)
      J Clin Pharm Ther. 2002 Aug;27(4):299-309. (PMID: 12174032)
      Antimicrob Resist Infect Control. 2019 Feb 12;8:35. (PMID: 30805182)
      Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S93-6. (PMID: 25261547)
      Clin Ther. 2013 Jun;35(6):751-7. (PMID: 23747075)
      J Glob Antimicrob Resist. 2014 Mar;2(1):1-6. (PMID: 27873630)
      Antimicrob Agents Chemother. 2007 Jun;51(6):1967-71. (PMID: 17420207)
      Am J Infect Control. 2017 Aug 1;45(8):917-922. (PMID: 28768593)
      Int J Clin Pharm. 2012 Apr;34(2):290-4. (PMID: 22382886)
      New Horiz. 1996 Aug;4(3):370-6. (PMID: 8856755)
      J Pediatric Infect Dis Soc. 2012 Sep;1(3):179-86. (PMID: 26619405)
      Unfallchirurg. 2017 Jul;120(7):540-548. (PMID: 28608289)
      Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543. (PMID: 28178770)
    • Grant Information:
      2015 Merck Sharp & Dohme Colombia
    • Contributed Indexing:
      Keywords: Antibiotic resistance; Antimicrobial resistance; Antimicrobial stewardship; Antimicrobial stewardship program; Colombia; Hospital epidemiology
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Anti-Infective Agents)
      75J73V1629 (Ceftriaxone)
      FV9J3JU8B1 (Meropenem)
    • Publication Date:
      Date Created: 20220503 Date Completed: 20220504 Latest Revision: 20220716
    • Publication Date:
      20231215
    • Accession Number:
      PMC9059380
    • Accession Number:
      10.1186/s12879-022-07410-6
    • Accession Number:
      35501756